Special Issue "Personalized Medicine Based on Drug Transporter Genetic Heterogeneity"
A special issue of Journal of Personalized Medicine (ISSN 2075-4426).
Deadline for manuscript submissions: closed (15 February 2019)
Prof. Dr. Marçal Pastor-Anglada
Molecular Pharmacology and Experimental Therapeutics, Department of Biochemistry and Molecular Biomedicine, Institute of Biomedicine (IBUB), University of Barcelona, Oncology Program, National Biomedical Research Institute on Liver and Gastrointestinal Diseases (CIBER EHD) and Institut de Recerca Sant Joan de Déu (IR SJD), Av. Diagonal 643, E-08028 Barcelona, Spain
Website | E-Mail
Interests: drug transporters; nucleoside analogs; anticancer therapy; antiviral therapy; mechanisms of drug action; nucleotide metabolism; oncogenesis
Prof. Dr. Matthias Schwab
Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart and Department of Clinical Pharmacology, Institute of Experimental and Clinical Pharmacology and Toxicology and Interfaculty Center for Pharmacogenomics and Drug Research (ICEPHA), University Hospital, Tuebingen Auerbachstrasse 112, 70376 Stuttgart, Germany
Phone: +49 711 8101 3700
Fax: +49-711-8592 95
Interests: pharmacogenomics/epigenetics of drug metabolizing enzymes; drug transporters and nuclear receptors; pharmacogenomics of anticancer and immunosuppressive drugs; drug interaction
The International Transporter Consortium (ITC) has indicated the need to implement easy and reproducible preclinical assays suitable for the analysis of drug-transporter interactions and drug–drug interactions likely to compromise drug pharmacokinetics and pharmacodynamics. These cross-interactions have been shown, in some cases, to have a clinical impact and may be also modulated by genetic polymorphisms in the transporter-encoding genes. The two major transporter-encoding gene superfamilies in humans, SLC and ABC, include paradigms of genetic heterogeneity, although their impact on drug action and their suitability as biomarkers of individual drug-response heterogeneity have not been properly addressed thus far. The Journal of Personalized Medicine is now opening a Special Issue that is fully devoted to drug transporter functional heterogeneity, with a call for papers involving basic, translational, and clinical research on this topic.
Prof. Marçal Pastor-Anglada and Prof. Matthias Schwab
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 550 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Neurological Diseases